We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
COVID-19 patients on intensive care support did not see improvement when given convalescent plasma, according to preliminary findings from the UK arm of a global trial. Read More
Pfizer and BioNTech now anticipate manufacturing up to 2 billion doses of their highly effective COVID-19 vaccine by the end of the year as vaccination efforts ramp up and demand for shots increases around the globe. Read More
The vaccine has received a conditional marketing authorization in the EU and is now being administered to high-risk groups in the EU member states. Read More
The FDA is currently working with test developers and conducting ongoing data analyses to evaluate all authorized tests, but said it believes there is only a low risk of mutations affecting overall testing accuracy. Read More
Pfizer/BioNTech’s COVID-19 vaccine should ideally be given in two doses 21 to 28 days apart, but due to ongoing shortages, an interval of up to 42 days is acceptable, the World Health Organization (WHO) said Friday. Read More
The European Union has secured 200 million more doses of the Pfizer/BioNTech COVID-19 vaccine, with an option to buy 100 million additional doses, bringing the total number of potential doses contracted for to 600 million. Read More
The UK’s National Health Service (NHS) will begin treating adult COVID-19 patients in intensive care with Roche’s and Sanofi’s arthritis medications following positive trial results that showed the drugs were highly effective when given early enough. Read More
Multiple COVID-19 vaccine developers are expected to file for regulatory approval in the coming months as the global pandemic continues its relentless advance. Read More
The UK has approved Moderna’s COVID-19 vaccine through a temporary authorization pathway, gaining a third option to add to approved vaccines from AstraZeneca/Oxford University and Pfizer/BioNTech. Read More
A study carried out by the University of Texas Medical Branch and Pfizer has found that the drugmaker’s COVID-19 vaccine still protects against a viral mutation that’s raised concerns around the world, though more research is needed. Read More
India’s Bharat Biotech has finalized enrollment for a phase 3 trial of its COVID-19 vaccine, Covaxin, which Indian regulators approved Jan. 3 for emergency use. Read More